RT Journal Article
T1 Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults.
A1 Vidal-Cortes, Pablo
A1 Martin-Loeches, Ignacio
A1 Rodriguez, Alejandro
A1 Bou, German
A1 Cantón, Rafael
A1 Diaz, Emili
A1 De la Fuente, Carmen
A1 Torre-Cisneros, Julian
A1 Nuvials, Francisco Xavier
A1 Salavert, Miguel
A1 Aguilar, Gerardo
A1 Nieto, Mercedes
A1 Ramirez, Paula
A1 Borges, Marcio
A1 Soriano, Cruz
A1 Ferrer, Ricard
A1 Maseda, Emilio
A1 Zaragoza, Rafael
K1 ICU
K1 KPC
K1 Klebsiella pneumoniae
K1 VAP
K1 Carbapenemase-producing Enterobacterales (CPE)
K1 Cefiderocol
K1 Ceftazidime-avibactam
K1 Imipenem-relebactam
K1 Meropenem-vaborbactam
K1 Nosocomial pneumonia
AB Infections due to Klebsiella pneumoniae have been increasing in intensive care units (ICUs) in the last decade. Such infections pose a serious problem, especially when antimicrobial resistance is present. We created a task force of experts, including specialists in intensive care medicine, anaesthesia, microbiology and infectious diseases, selected on the basis of their varied experience in the field of nosocomial infections, who conducted a comprehensive review of the recently published literature on the management of carbapenemase-producing Enterobacterales (CPE) infections in the intensive care setting from 2012 to 2022 to summarize the best available treatment. The group established priorities regarding management, based on both the risk of developing infections caused by K. pneumoniae and the risk of poor outcome. Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
PB MDPI
SN 2079-6382
YR 2022
FD 2022-08-25
LK http://hdl.handle.net/10668/20765
UL http://hdl.handle.net/10668/20765
LA en
NO Vidal-Cortés P, Martin-Loeches I, Rodríguez A, Bou G, Cantón R, Diaz E, et al. Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults. Antibiotics (Basel). 2022 Aug 27;11(9):1160
DS RISalud
RD Apr 14, 2025